MUC1 oncoprotein is a druggable target in human prostate cancer cells. - Wikidata - awgldk - TriplyDB

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

http://www.wikidata.org/entity/Q37437966

about

Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH Mucins in cancer: function, prognosis and therapy Prostate cancer relevant antigens and enzymes for targeted drug delivery The Role of Galectin-1 in Cancer Progression, and Synthetic Multivalent Systems for the Study of Galectin-1 Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation Origin of anti-tumor activity of the cysteine-containing GO peptides and further optimization of their cytotoxic properties.Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors.Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function.MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR Protein mislocalization: mechanisms, functions and clinical applications in cancer.EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.MUC1c regulates cell survival in pancreatic cancer by preventing lysosomal permeabilization.Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop.Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells Molecular Validation of PACE4 as a Target in Prostate Cancer Transmembrane mucins as novel therapeutic targets Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer.Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition.Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.Mucins in pancreatic cancer and its microenvironment.MUC1 (CD227): a multi-tasked molecule.Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231.Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo.Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells Glycodendrimers: tools to explore multivalent galectin-1 interactions Implication of Soluble Forms of Cell Adhesion Molecules in Infectious Disease and Tumor: Insights from Transgenic Animal Models.MUC1: The First Respiratory Mucin with an Anti-Inflammatory Function.

P2860

Q24603767-D7DE8993-822A-453A-817B-3474A0D0E3AC Q24633765-4097A629-A5BE-4D07-A6E1-9C8CF4346FC6 Q27013843-CE4DD42B-1914-42DB-8DD5-0D677E7A6852 Q28075523-AC7B01EF-E7E8-4FD3-9244-F16E7DBEAAFE Q28394194-6694A088-D03E-4EAA-9DD2-5913006F06AF Q29248355-0C0B6874-9709-44F5-AB52-14FB262C6A8D Q33827824-602E6860-15F3-49CD-A24B-4E5F03236107 Q34051633-7E1EE2BB-29AC-473E-92A1-2DECA82FC871 Q34073802-E797E9B0-2450-41FA-9116-048DE7D00EEB Q34076405-A3B8C0EF-4424-4A9F-9CE6-D29DBA29D7AB Q34269196-4C984A17-486A-4BEF-892A-1E8106CC1A4E Q34389169-09D33EE6-F2C6-4C9E-88D4-25507AD44704 Q34555770-A67FB98A-5B29-4C71-9680-785D825C1B62 Q34759460-E72A2A19-BAFB-4AEC-9E75-736A08B84B19 Q34970672-3B294188-78FC-4E60-A17E-F9D96D5CBF17 Q35001632-2D1D8336-ED25-4197-B3DE-56FE148948A0 Q35015483-2FEF0D2A-8C19-484E-9766-033F7B1BA361 Q35632645-F06C20D4-F3CD-46D1-B85C-A30D85C1BC7E Q35853834-BEE70F89-DA82-417A-A846-44B2B85F413A Q35888913-75FC33E6-B1B3-4F93-B6EA-679BF58D7EB1 Q36146986-FF835D0E-88AA-4DD9-AA2A-A204C4AE8AB2 Q36152246-FB89B146-5F78-44DF-889B-BC74C2CB917D Q36237322-D31BC112-90B2-41D0-B7A0-5032C9EC988E Q36608702-A0730439-5E22-4F86-954F-DD03E6FA6F62 Q36753508-B9F49504-F0C4-4C96-A0AF-68CB3800FD97 Q36821095-7579682F-3C12-4CC7-9724-15289CABE2C6 Q37022006-A0046825-F6A6-4081-B38F-95328B378B2A Q37071139-733D8793-9007-470B-B3FB-30E9BC6986ED Q37096479-94B4CFCA-80E1-4424-BD5C-C241D68D9DD8 Q37622949-869F7BA1-920E-427B-A9BB-651948635CAB Q38121746-6EDCE37D-EFDD-4DAD-97E7-DF3B11E20006 Q38570769-2EA571D2-57B0-4CD2-9D54-79A952A60187 Q38695753-1E6A3F65-1A62-47B6-ABF0-65AF6AB778A7 Q38946727-5D1069E1-BB0F-4AC2-A9EC-339FB2551D4F Q39467521-5DD09CC8-CBE7-44B4-8276-0665935858AB Q39594994-D4F72241-8092-42D2-97CC-7901282F73EF Q41925209-35C8158F-81D4-4524-BD92-023B8EEE6A22 Q47552397-27909771-088B-4C88-AC08-AADD16773852 Q47696532-78D2EDCD-93B9-456F-AEA2-BD39A1B72BA9

P2860

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

http://www.wikidata.org/entity/Q37437966

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

@en

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

@nl

type

label

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

@en

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

@nl

prefLabel

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

@en

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

@nl

P1433

Q37437966-DAF8AD8D-E89F-4A59-8651-E4A84F6176E9

P1476

Q37437966-C21FF16A-398E-4090-8560-F6583A20483D

P2093

Q37437966-1A625E3A-CA6D-41D3-A4B9-8923790F2284

Q37437966-36558576-33B3-4A75-81C1-A9C5F2730BAB

Q37437966-66DA5AAD-7778-44F5-9A64-CF844AD1E2AC

Q37437966-9A34DABE-B1AE-4125-9638-F7581B7EA520

Q37437966-B0E11258-E1FB-483F-96F9-062734B1EBEB

Q37437966-E30A98EB-E6ED-43B9-9A53-18CAA531BBD2

Q37437966-EB4F64DD-A2D0-4B09-8630-79DDE194A033

Q37437966-F3BBBAE3-5811-486E-9D7F-572360D444B6

P2860

Q37437966-014E12CE-4F9B-4582-9FB9-F25FEA28FC9A

Q37437966-0265A60D-D871-4450-85B4-B2EDCAB3BED7

Q37437966-02C08DF6-7978-4A3B-B657-9205B34BBBBB

Q37437966-031766E3-2088-4A16-A0CA-86056B168C0E

Q37437966-066E7B3C-D42C-430E-8273-BC98B1150C19

Q37437966-0677B3FC-3E8D-41D8-8DCC-2B918CC5546A

Q37437966-1194E40E-8A80-4382-AC34-5596AD697823

Q37437966-136E336E-C94B-44AF-98EA-02628250C0B1

Q37437966-18C4DA01-DBE5-4B50-BD01-931C21711057

Q37437966-198A42BE-28F7-4392-821E-AF9C3DB27868

P304

Q37437966-A4A625B7-90FD-4F7B-B63E-C109AD7F72E2

P31

Q37437966-E6B1B21E-D3D3-46C1-B8F3-EE4461CDAD46

P356

Q37437966-2EDDBC60-6902-4FD4-8843-B6181B05DABF

P433

Q37437966-9272F7F5-3C6A-410B-B2A6-004E77E5F5D0

P478

Q37437966-EFA2CAC4-A2BD-4B7F-84DC-CF96801044D3

P577

Q37437966-14297B00-CEEF-4A29-8EF2-3AA7738BE05E

P698

Q37437966-42BBFFD3-F91B-412F-B62C-B0611DA9BD67

P932

Q37437966-6649BDDF-B014-4C1B-8CCC-62E79161B09B

P356

1535-7163.MCT-09-0646

P1433

Molecular Cancer Therapeutics

P1476

MUC1 oncoprotein is a druggable target in human prostate cancer cells.

@en

P2093

Deepak Raina

http://www.w3.org/2001/XMLSchema#string

Donald Kufe

http://www.w3.org/2001/XMLSchema#string

Glenn Bubley

http://www.w3.org/2001/XMLSchema#string

Hasan Rajabi

http://www.w3.org/2001/XMLSchema#string

Li Yin

http://www.w3.org/2001/XMLSchema#string

Maya Datt Joshi

http://www.w3.org/2001/XMLSchema#string

Rehan Ahmad

http://www.w3.org/2001/XMLSchema#string

Surender Kharbanda

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-catenin affects androgen receptor transcriptional activity and ligand specificity

Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response

Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin

Linking beta-catenin to androgen-signaling pathway

Molecular determinants of resistance to antiandrogen therapy

Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion

MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90

MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin

P304

3056-3065

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-09-0646

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19887552

http://www.w3.org/2001/XMLSchema#string

P932

2783220

http://www.w3.org/2001/XMLSchema#string